Analyst Andrew Tsai from Jefferies maintained a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report) and keeping the price target at $40.00.
Andrew Tsai has given his Buy rating due to a combination of factors that suggest promising growth prospects for Supernus Pharmaceuticals. One of the primary drivers is the anticipated sales growth of Qelbree in the ADHD market, with expectations of significant revenue potential. The extension of Qelbree’s patent until 2035 provides additional time for the company to expand its pipeline offerings.
Furthermore, the upcoming launch of Onapgo for Parkinson’s disease is expected to contribute positively to the company’s financial performance, with a substantial market opportunity. The company’s strategic positioning in the central nervous system and neuro pipeline, along with potential business development deals, further supports the positive outlook. These elements collectively underpin Tsai’s optimistic assessment of Supernus Pharmaceuticals’ stock.
In another report released on February 25, TD Cowen also maintained a Buy rating on the stock with a $44.00 price target.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SUPN in relation to earlier this year.